Oncolytics Biotech (ONCY)
(Delayed Data from NSDQ)
$1.09 USD
+0.03 (2.83%)
Updated May 24, 2024 04:00 PM ET
After-Market: $1.08 -0.01 (-0.92%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Oncolytics Biotech Inc. [ONCY]
Reports for Purchase
Showing records 21 - 40 ( 143 total )
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
Positive Data Presented at AACR on Lead Candidate Pelareorep Points to Potential Beyond Lead Breast Cancer Indications
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
4Q21 Results; Pipeline Progressing; Lead Breast Cancer Program BRACELET-1 on Track to Generate Top-Line Data in 4Q22
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
Preclinical Data Demonstrates Benefit of Combining Oncolytic Agent Pelareorep With Chemotherapy in AML Animal Models
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
3Q21 Results; Reports Positive Biomarker Data, Pelareorep Oncolytic Virus Data Updates on Track for 4Q21 and 2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
Positive Preclinical Data Demonstrates Synergy of Pelareorep With Radiotherapy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
2Q21 Results; Lead Breast Cancer Programs Advancing; Safety Updates Expected 4Q21; Efficacy Updates Expected in 2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
1Q21 Results; Pelareorep Demonstrates Potential to Turn Cold Tumors Hot; Multiple Updates on Track for 2H21 and 2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
Pelareorep Data Updates Highlight Potential Synergy with Immunotherapies; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
Breast Cancer Program Updates, Potential CART Collaborations, to Drive Robust Upside; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
Cancer Killing Bug Just What the Doctor Ordered; Initiating With a Buy and $15 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
Pelareorep/Carfilzomib Elicits Tumor Responses in Difficult-to-Treat RRMM
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
Pelareorep May Afford Breast Cancer Patients a Better Response to CPIs
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
ONCY and INO: ASCO 2020 Abstracts Relevant to Our Coverage Universe
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J